Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.

about

Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.

Item

http://www.wikidata.org/entity/Q38924049

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Analysis of esophagogastric ca ...... gram sponsored phase 1 trials.

@en

type

Item

label

Analysis of esophagogastric ca ...... gram sponsored phase 1 trials.

@en

prefLabel

Analysis of esophagogastric ca ...... gram sponsored phase 1 trials.

@en

P1476

Analysis of esophagogastric ca ...... gram sponsored phase 1 trials.

@en

P2093

Atsushi Ohtsu

http://www.w3.org/2001/XMLSchema#string

Hideaki Bando

http://www.w3.org/2001/XMLSchema#string

John Welch

http://www.w3.org/2001/XMLSchema#string

Larry Rubinstein

http://www.w3.org/2001/XMLSchema#string

Naoko Takebe

http://www.w3.org/2001/XMLSchema#string

Pamela Harris

http://www.w3.org/2001/XMLSchema#string

Takayuki Yoshino

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cancer statistics, 2013

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.

Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit.

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

P2888

s10120-016-0629-x

P304

481-488

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-016-0629-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Toshihiko Doi

P577

2016-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1034216472

http://www.w3.org/2001/XMLSchema#string

P698

27510411

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial